AVF Needles Low Unit Cost, High Reorder

Hypodermic needle procurement is typically "nursing + infection control + purchasing," at fractions of a cent per piece, millions/year - decision centers on "compliance + unit price." AVF needles differ: unit cost $0.35–2.50, a dialysis patient uses 312 needles/year (2 needles × 3 sessions/week × 52 weeks), an 80–90 patient/100-station center consumes ~25–28K needles/year - lower volume than hypodermic (no millions) but with "patient loyalty 4yr+" and "needle + dialyzer + tubing + puncture kit are a bundled set." The decision chain is a four-player game:

1. Nephrologist (Chief of Nephrology) - Owner of Fistula Patency

He doesn't directly specify needles but cares deeply if "this year's fistula thrombosis rate is up again." If it rises, he'll ask the head nurse: "Is the needle too sharp and scraping the intima? Is the buttonhole needle type wrong?" - his latent influence is over "tip geometry selection" (Rochester / Taper / bullet) and "side-hole yes/no." When meeting the nephrologist, don't sell on unit price - present: "Our 17G bullet + 2 side holes showed 72% 5-year fistula patency vs. 64% with standard sharp tip in a Japanese center."

2. Dialysis Head Nurse - The Real Decider

She oversees cannulation, tracks complications, manages needlestick injuries among staff, and controls monthly consumable requisitions. Her KPIs: ① Cannulation success (new nurse learning curve) = tip consistency & stability; ② Post-removal track bleeding = electropolish + bevel marking; ③ Staff needlesticks = need for Gen-3 safety needles; ④ Cost = bundled price (needle + wing + tubing). If she endorses a brand, purchasing won't overturn it - the key difference from hypodermic needles, where nurse influence is limited (high volume, commodity, infection control-led). On AVF, head nurse influence is decisive.

3. Purchasing / GPO - Price Execution Layer

AVF needles are rarely tendered alone; they ride in a "dialysis consumables pack" (dialyzer + tubing + AVF needle + puncture kit + heparin cap). A $0.10/needle price difference impacts <1% of the total pack cost - so purchasing has little motivation to aggressively squeeze AVF needle price; whether "the pack satisfies both the nephrologist and head nurse" matters more. Domestic makers selling only AVF needles (not the rest of the pack) struggle to enter GPO bids; Weigao and Baihe bundle "dialyzer + tubing + needle," allowing AVF needles to ride the pack's volume.

4. Payer / Medical Insurance - The Invisible Ceiling

Domestic AVF needle reimbursement is ~¥2.5–8/needle (Gen-1 to Gen-3). Gen-3 safety needles lack a separate reimbursement code, so tertiary hospitals resist the out-of-pocket differential. In the West, Nordic/German states reimburse the safety needle premium - that's why Gen-3 gains traction there.

For Brand/OEM:​ Don't chase provincial tenders with AVF needles alone. Either enter as a sub-component of the "dialysis consumables pack" (ride the dialyzer maker's bid), or directly engage head nurses with in-service training (sample needles + fistula-type matching table + bevel-orientation training). If you do neither, even the cheapest unit price won't get you in.